Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer

Jun Hwa Lee; Yun Hwan Kim; Kyung-Hee Kim; Jae Youl Cho; Sang Myung Woo; Byong Chul Yoo; Seung Cheol Kim

doi:10.4143/crt.2017.275

Articles

Page Path: HOME > Cancer Res Treat > Volume 50(3); 2018 > Article

Original Article Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer: Jun Hwa Lee, PhD¹, Yun Hwan Kim, MD, PhD², Kyung-Hee Kim, PhD¹, Jae Youl Cho, PhD³, Sang Myung Woo, MD, PhD¹, Byong Chul Yoo, PhD^1,, Seung Cheol Kim, MD, PhD^2,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2018;50(3):883-893.
DOI: https://doi.org/10.4143/crt.2017.275
Published online: September 18, 2017

¹Biomarker Branch, Research Institute, National Cancer Center, Goyang, Korea

²Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea

³Department of Genetic Engineering, Sungkyunkwan University, Suwon, Korea

Correspondence: Byong Chul Yoo, PhD Biomarker Branch, Research Institute, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: 82-31-920-2342 Fax: 82-31-920-2354 E-mail: yoo_akh@ncc.re.kr

Co-correspondence: Seung Cheol Kim, MD, PhD Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea
Tel: 82-2-2650-5587 Fax: 82-2-2650-5963 E-mail: onco@ewha.ac.kr

*Jun Hwa Lee, Yun Hwan Kim, and Kyung-Hee Kim contributed equally to this work.

• Received: June 7, 2017 • Accepted: September 10, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

11,258 Views
248 Download
10 Web of Science
9 Crossref
9 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
We sought to develop a matrix assisted laser desorption ionization-time of flight (MALDI-TOF)-based, ovarian cancer (OVC), low-mass-ion discriminant equation (LOME) and to evaluate a possible supportive role for triple-TOF mass analysis in identifying metabolic biomarkers.
Materials and Methods
A total of 114 serum samples from patients with OVC and benign ovarian tumors were subjected to MALDI-TOF analysis and a total of 137 serum samples from healthy female individuals and patients with OVC, colorectal cancer, hepatobiliary cancer, and pancreatic cancer were subjected to triple-TOF analysis. An OVC LOME was constructed by reference to the peak intensity ratios of discriminatory low-mass ion (LMI) pairs. Triple-TOF analysiswas used to select and identify metabolic biomarkers for OVC screening.
Results
Three OVC LOMEs were finally constructed using discriminatory LMI pairs (137.1690 and 84.4119 m/z; 496.5022 and 709.7642 m/z; and 524.5614 and 709.7642 m/z); all afforded accuracies of > 90%. The LMIs at 496.5022 m/z and 524.5614 m/z were those of lysophosphatidylcholine (LPC) 16:0 and LPC 18:0. Triple-TOF analysis selected seven discriminative LMIs; each LMI had a specificity > 90%. Of the seven LMIs, fourwith a 137.0455 m/z ion atretention times of 2.04-3.14 minuteswere upregulated in sera from OVC patients; the ion was identified as that derived from hypoxanthine.
Conclusion
MALDI-TOF–based OVC LOMEs combined with triple-TOF–based OVC metabolic biomarkers allow reliable OVC screening; the techniques are mutually complementary both quantitatively and qualitatively.
Key words: Ovarian neoplasms, Low-mass ions, Serum metabolite, Hypoxanthine, Mass spectrometry

Introduction

Epithelial ovarian cancer (OVC) is the fourth most common cause of death from cancer in Western women. Over 70% of patients are diagnosed at advanced stages; the 5-year survival rate is < 30%. As epithelial OVC has few specific symptoms, the challenge is to detect OVC early to improve clinical outcomes [1].

Various screening methods including measurements of serum tumor and proteomic markers, and ultrasonography, have been developed and intensively investigated. A strategy combining serum tumor marker levels with ultrasonography has shown most promise; large-scale randomized clinical trials have been conducted. The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) featuring annual carbohydrate antigen 125 (CA-125) measurement and second-line transvaginal ultrasound scanning afforded sensitivity of 89.5% and specificity of 99.8% among postmenopausal women, but primary analysis indicated that any reduction in mortality was not statistically significant [2,3]. Similar trials have been performed in the United States. For example, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening study found that simultaneous screening of the CA-125 level and transvaginal ultrasonography (compared with the usual care) did not reduce OVC mortality in post-menopausal women, and false-positive data were associated with various complications [3]. A recent 15-year follow-up PLCO report showed that mortality was not reduced by CA-125/ultrasonographic screening [4].

Thus, no reliable screening method exists and a noninvasive method is urgently required. Recently, we reported that a low-mass ion discriminant equation (LOME) might allow early detection of OVC [4]. In our previous study, we performed matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass analysis on metabolic low-mass ions (LMIs) using 1,184 serum samples from healthy individuals and patients with OVC or other types of cancer [4]. An OVC LOME derived using 13 discriminatory LMIs yielded excellent results. Among 13 LMIs exhibiting differential mass intensities in OVC patients, three (LPC 16:0, D,L-glutamine, and the fibrinogen alpha-chain fragment) were identified and semi-quantitated [4].

In the present study, we focused on modification and validation of the MALDI-TOF‒based OVC LOME, and we also compared MALDI-TOF and triple-TOF analyses discriminating OVC.

Materials and Methods

1. Study population

A total of 114 serum samples from women with OVC and benign ovarian tumors (BOTs) were subjected to MALDITOF analysis (Table 1, S1-S3 Tables). A total of 137 serum samples from healthy women (controls) and those with OVC, colorectal cancer (CRC), hepatobiliary cancer (HBC), and pancreatic cancer (PC) were subjected to triple-TOF analysis (Table 2, S4-S9 Tables). The OVC groups differed between the two analyses. HBC and PC included high risk groups. Samples were collected before surgery or chemotherapy to prevent any effects of anesthetics or anticancer agents on the LMIs of sera. Some resources were provided by the Korean Gynecological Cancer Bank through the Bio & Medical Technology Development Program of the Ministry of Science, ICT and Future Planning, South Korea.

2. Separation of the OVC from the BOT group using MALDI-TOF data

The manner in which we formulated a LOME separating the OVC and BOT groups differed significantly from that of our previous study [5], although the basic ideas and many procedures were similar. The modified methods were described in the following parts 4 and 5.

3. MALDI-TOF and triple-TOF analyses

MALDI-TOF (Autoflex Speed, Bruker Daltonik GmbH, Bremen, Germany) and triple TOF 5600+ system (AB SCIEX, Framingham, MA) analyses were performed as described previously [5,6] (see more details in Supplementary Methods).

4. Preliminary LMI candidates

Principal component analysis–based discriminant analysis (PCA-DA) was performed to discriminate the OVC from the BOT group. The groups were not divided into training and validation sets, as the sample numbers were rather small. Six repetitive sets of measurement data were respectively analyzed. When performing PCA-DA, it is necessary to import mass spectra into MarkerView software (AB SCIEX, Foster City, CA). During this process, we chose the following settings: mass tolerance, 300 ppm; minimum required response, 10.0; and maximum number of peaks, 10,000. Data in the resulting peak table were converted into common logarithms and Pareto-scaled. A zero mass intensity was set to unity because Log₁₀(0) is undefined and Log₁₀(1) is zero. The Markerview software accepts only natural logarithms; the reference manual deals with PCA-DA and Pareto scaling.

The PCA-DA discriminant score (DS) was the weighted sum of the Pareto-scaled intensities of all LMIs (≤ 10,000). Usually, a few percent of the LMIs play a crucial role in calculation of the DS. Search algorithm I selected preliminary LMI candidates using two criteria: (1) weighted intensities > 0.018 for each sample and (2) LMIs common to > 50% of the entire sample. The 0.018 threshold was empirically determined in an iterative manner; we explored how various thresholds changed the numbers of candidate LMIs and their performance in terms of classification. Search algorithm I was individually applied to the six PCA-DA results and the resulting LMIs were assembled into a preliminary candidate set of P LMIs by replacing multiple LMIs with similar mass values by an averaged mass value.

5. Discriminative LMIs derived using MALDI-TOF data

A peak table was prepared for each sample by sequentially importing the six repetitions. Each peak table was normalized using the “total area sums” method described in the reference manual. The six mass intensities of all preliminary LMI candidates were extracted and processed as follows: (1) the ranges of mass values ±0.5 m/z were determined; (2) the maximum normalized intensity was determined for every repetition in the interval; (3) the mean of the six maximum intensities was calculated (the averaged intensity); and (4) the common logarithm of the averaged intensity was calculated. Throughout this process, a column of the logarithmic intensities of P LMI candidates was built for each sample and then merged into a single peak table for the entire sample.

Several LOMEs derived using the ratio of two discriminant LMIs were constructed with the aid of the logarithmic peak table. Search algorithm II identified the two LMIs as follows: (1) The _PC₂ combinations were listed and every pair of LMIs was evaluated twice. One of the two LMIs was initially arbitrarily chosen as the numerator in the first round and the denominator in the second. (2) Every pair in the list was investigated sequentially. The ratios of the common logarithms of all paired LMIs were calculated to yield DSs. (3) We identified a threshold with a resolution of 0.01 that maximized the sum of the sensitivity and specificity. If more than one threshold afforded the same performance, the thresholds were averaged. (4) The two ordered pairs, the thresholds, and their sensitivity and specificity sums were tabulated for later comparison. (5) A few discriminative pairs were identified by comparing the discriminatory performances of all ordered pairs.

6. Distinguishing OVC from non-OVC patients using triple-TOF data

Triple-TOF measurements were performed only once on each sample, unlike the procedure described above during MALDI-TOF evaluation. We did not select preliminary LMI candidates; our focus was on defining a single LMI, the pattern of which differed between the OVC and non-OVC (control/CRC/HBC/PC) groups.

7. Discriminative LMIs identified using the triple-TOF data

Liquid chromatography/mass spectrometry (LC/MS) peak lists (.peaks files) were first created for all samples (.wiff files) using MarkerView software running under the following constraints: minimum retention time, 0.00 minute; subtraction offset, 10 scans; subtraction mult. factor, 1.3; noise threshold, 10; minimum spectral peak width, 10 ppm; and minimum retention time peak width, 5 scans. Next, a peak table was created by simultaneously importing the LC/MS peak lists for all samples. The parameters for the second process were as follows: retention time tolerance, 0.01 minute; mass tolerance, 10.0 ppm; intensity threshold, 10; and maximum number of peaks, 20,000. Areas were derived using raw data, not the original peak findings, as suggested by the reference manual. The resulting peak table was normalized using the “total area sums” method and the data converted to common logarithms. As for MALDI-TOF, a zero peak area was set to unity.

Several LMIs exhibiting individually acceptable discriminatory abilities were searched using the logarithmic peak table (consisting of 7,018 LMIs). Search algorithm III was straightforward. (1) For each LMI, a threshold with a resolution of 0.01 was chosen at which the sum of the sensitivity and specificity was maximized. If more than one threshold exhibited the same discriminatory performance, the thresholds were averaged. (2) A few discriminatory LMIs were identified by comparing the performances of all LMIs. As an initial check, their locations on the volcano plot and/or their Fisher’s discriminant ratios (FDRs) were evaluated.

8. Identification of metabolite ions

The mass spectrometry (MS) and tandem mass spectrometry (MS/MS) spectra were explored using Formula Finder computational tools (AB SCIEX) that identify probable elemental compositions within specified mass tolerances of a given mass-to-charge ratio using PeakView software. The Human Metabolome Database (HMDB) identified compounds associated with given m/z ratios, and listed them in rank order based on the MS and MS/MS data.

9. Statistics

A volcano plot was created and the associated t-test performed using data from the normalized peak table (not the logarithmic table), employing MarkerView software (AB SCIEX).

10. Ethical statement

Informed consent was obtained from all participants, and the institutional review board of each participating institution approved the research protocol.

Results

1. Preliminary LMI candidates

The discriminations afforded by PCA-DA (sensitivity, 96.49%; specificity, 91.23%) and Search algorithm I (sensitivity, 91.23%; specificity, 94.74%) are shown in Fig. 1 for one of the representative six repeat measurements. All LMIs in the peak table were included in the PCA-DA DSs. Unlike when the mass intensity per se was used [5,6], the DS range fell noticeably when Search algorithm I rather than the PCA-DA was employed (logarithmic intensities were analyzed). However, the marked decrease in the number of LMIs did not greatly reduce the discriminatory capacity. Individual applications of Search algorithm I to the six repetitions, followed by assembly of the resulting LMIs, yielded 374 preliminary candidates.

2. Ratios of the discriminatory LMI pairs yielded by the MALDI-TOF data

Search algorithm II identified several pairs of discriminatory LMIs (Fig. 2) between the OVC and BOT groups. The separation performances of three such pairs are summarized in Table 3. In all cases, the accuracies were > 90%. Overall, the logarithmic intensities of the numerator LMIs were higher in the OVC than in the BOT group and the reverse was true for the denominator LMIs. The numerator LMIs of 496.5022 m/z and 524.5614 m/z were earlier identified as lysophosphatidylcholine (LPC) 16:0 and LPC 18:0 [5,6]. Different tumor stage did not lead to significant change in screening sensitivity and specificity (Fig. 2).

3. Individual discriminative LMIs derived using triple-TOF data

Search algorithm III identified seven LMIs (Fig. 3A) differentiating between the OVC and control/CRC/HBC/PC groups; the overall specificity was > 90%. There was no significant change in screening sensitivity and specificity according to tumor stage (Fig. 3A). LMI with 381.1314 m/z only showed a pattern of decrease in late stage, i.e., stage I vs. III (p=0.006), stage I vs. IV (p=0.045) and stage II vs. III (p=0.01) (Fig. 3A). Table 4 shows the discriminatory performances. Overall, the logarithmic peak areas of the first five LMIs were higher in OVC than in non-OVC patients and the reverse was true for the other two LMIs. In particular, the latter two LMIs exhibited excellent separation capabilities. Accordingly, when these LMIs were used as denominators (as in MALDI-TOF evaluation), their performances were outstanding. For all 10 (5×2) cases, the accuracies were > 98% (thus, no more than two false-positives/100 patients), as expected. The associated volcano plot (Fig. 3B) and the high FDR (Table 4) confirmed these findings. The fourth and fifth LMIs are not highlighted on the volcano plot (unlike the other five) because the Log₁₀(-fold change) of the first LMI was very close to those of LMIs 2 and 3; they could not be individually visualized.

4. Metabolites discriminating OVC from BOT

Triple-TOF analysis revealed that seven single LMIs potentially discriminated OVC from BOT (Table 4). A search of the HMDB using the exact LMI masses revealed several candidate metabolites (Table 5). Of these, four with a 137.0455 m/z ratio at retention times of 2.04-3.14 minutes were upregulated in serum from OVC patients (Fig. 3). The HMDB identified hypoxanthine as the metabolite corresponding to these LMIs (Table 5). We used MS/MS to confirm this finding; the MS/MS pattern of the LMIs at 137.0455 m/z was identical to that of hypoxanthine (Fig. 4).

Discussion

We selected preliminary LMI candidates by aligning the mass peaks of all samples with each mass value. We did not simultaneously import all six repeats when creating a peak table using MarkerView software. PCA-DA and Search algorithm I were employed to this end (Fig. 1). However, this did not necessarily identify a monoisotopic peak on the main lobe. In fact, the three numerator LMIs were present as monoisotopic peaks on the side lobe of second- highest intensity, thus at 138.1754 m/z, 497.5082 m/z, and 525.5643 m/z. This was also the case in our previous studies [5,6], but there is no reason to insist that only these LMIs should be used; completely new approaches are possible.

MALDI-TOF did not yield any unique LMI affording acceptable performance. We limited the number of LMIs used to create a LOME to two, formulated as a ratio (Fig. 2). The method can be easily extended to the creation of new LOMEs including more than two LMIs; however, the ratio approach would not then be appropriate. For example, the ratio can be replaced by an algebraic sum of the signed logarithmic intensities. In addition, the number of PCI combinations will increase sharply with increasing I, where I is the number of LMIs used to compose a LOME. Accordingly, it is important to reduce candidate LMIs using methods such as PCA-DA and Search algorithm I.

It is not possible to compare the MALDI-TOF and triple-TOF data directly; the OVC countergroups differed. In triple-TOF analysis, the ratio scheme was implemented without selection of candidate LMIs (thus, the intermediate step was omitted) after identification of individual discriminatory LMIs. However, the reduction step may be useful when the goal is to apply a ratio or other multi-LMI scheme directly. In addition, it is much more time-consuming to create a peak table for triple-TOF than for MALDI-TOF data. Therefore, any peak table should be used for various purposes, such as multi-cancer screening on single samples; in males, analysis of serum samples will also be required. MALDI-TOF consumes less analytical time than triple-TOF and more samples can be analyzed on a single MALDI target plate. However, we recently found that reproducibility is affected by MS hardware such as the laser source and laser power unit. Thus, we sought to apply LOME to triple-TOF analysis to enhance analytical repeatability and to identify candidate metabolites for inclusion in LOMEs. The analytical tools are mutually complementary.

A screening test for OVC must be highly specific and highly sensitive, to avoid needless surgery. As the incidence of epithelial OVC is low, the positive predictive value of multimodal screening was only 35.1%, but the sensitivity and specificity were as high as 89.5% and 99.8%, respectively, in the UKCTOCS trial [2]. In the present study, we show that LOME may overcome the shortcomings of other noninvasive screening tests, without any need for imaging. The sensitivity and specificity may reach 98% if the optimal discriminatory equation is selected. Furthermore, the hypoxanthine LMI discriminated OVC from non-OVC patients (Figs. 3 and 4). Hypoxanthine is a natural purine derivative, and an intermediate in adenosine metabolism and nucleic acid synthesis via the salvage pathway (http://www.hmdb.ca/). We previously identified hypoxanthine as a useful serum biomarker of the chemoresponsiveness of locally advanced rectal cancer [7], and as a valuable urine biomarker when screening for non-Hodgkin lymphoma [8]. The urinary hypoxanthine level may be a marker of gastrointestinal tumors [9,10]. Recent metabolic profiles of ovarian cyst fluid samples from benign, borderline, and malignant ovarian tumors showed that hypoxanthine was present only in a sub-cohort of malignant tumors [11]. Our findings support the suggestion that high serum hypoxanthine levels may be indicative of OVC (Figs. 3 and 4). Furthermore, a higher hypoxanthine concentration correlated with a good chemoresponse in patients with locally advanced rectal cancer [7]. In OVC patients, hypoxanthine completely reversed the cytotoxicity induced by methotrexate and methotrexate plus dipyridamole [12]. Unfortunately, the sample size of the present OVC group was too small to allow us to explore links between the hypoxanthine level and clinicopathological factors including chemoresponse and stage. However, we expect that several candidate markers identified and to be identified may have a potential for screening OVC in early stage. For example, Metabolite with 381.1314 m/z showed a pattern of decrease in late stage (Fig. 3A). Therefore, future work on this issue is thus needed.

In conclusion, a MALDI-based LOME exhibited good potential as a noninvasive screening test for OVC, and triple-TOF-based metabolite analysis successfully identified OVC biomarkers.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

crt-2017-275-suppl1.pdf

crt-2017-275-suppl2.pdf

crt-2017-275-suppl3.pdf

crt-2017-275-suppl4.pdf

crt-2017-275-suppl5.pdf

crt-2017-275-suppl6.pdf

crt-2017-275-suppl7.pdf

crt-2017-275-suppl8.pdf

crt-2017-275-suppl9.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This work was supported by grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C0050).

Fig. 1.

Separation results obtained during one of the six repeats of matrix assisted laser desorption ionization-time of flight analysis. (A) Principal component analysis-based discriminant analysis (PCA-DA). (B) Preliminary low-mass-ion candidates. DS, discriminant score; OVC, ovarian cancer; BOT, benign ovarian tumor.

Fig. 2.

Discriminatory results afforded by the ratios of low-mass ion pairs on matrix assisted laser desorption ionization-time of flight analysis. (A) Log₁₀(137.1690 m/z)/Log₁₀(84.4119 m/z). (B) Log₁₀(496.5022 m/z)/Log₁₀(709.7642 m/z). (C) Log₁₀ (524.5614 m/z)/Log₁₀(709.7642 m/z). OVC, ovarian cancer; BOT, benign ovarian tumor.

Fig. 3.

Seven candidate metabolites suggested by triple-TOF analysis to be characteristic of ovarian cancer (OVC). (A) Figure shows relative amount of each candidate metabolites [Y-axis, Log₁₀(mass peak area of low-mass ion)] in healthy women (control) and those with OVC, colorectal cancer (CRC), hepatobiliary cancer (HBC), and pancreatic cancer (PC). Low-mass ions (LMIs) of 137.0455 m/z, retention time (RT) 2.04 min; 138.0497 m/z, RT 2.46 min; 159.0270 m/z, RT 2.46 min; 137.0461 m/z, RT 2.07 min; 137.0454 m/z, RT 3.14 min; 359.1413 m/z, RT 15.27 min; 381.1314 m/z, RT 15.30 min. Of the seven LMIs, four with a 137.0455 m/z ion at RTs of 2.04-3.14 min were upregulated in sera from OVC patients; those LMIs were identified as hypoxanthine. (B) A volcano plot of low-mass ions detected on triple-TOF analysis.

Fig. 4.

Identification of hypoxanthine upregulated in sera of ovarian cancer (OVC) patients. A low-mass ion of 137.0455 m/z (left panel, B) exhibited a retention time (RT) that differed slightly from that of hypoxanthine (left panel, A), but the tandem mass spectrometry (MS/MS) pattern (right panel, B) was exactly that of hypoxanthine (right panel, A).

Table 1.

Demographic data on study participants evaluated via MALDI-TOF analysis

	Total	Stage				Age (yr)
	Total	I	II	III	IV	Mean±SD	Range
OVC	57	11	2	37	7	54.7±10.1	27-76
BOT	57	-	-	-	-	41.7±14.2	20-83

Supplementary information on individual participants is given in S1 and S2 Tables. S3 Table lists the sample collection sites.

MALDI-TOF, matrix assisted laser desorption ionization-time of flight; SD, standard deviation; OVC, ovarian cancer; BOT, benign ovarian tumor.

Table 2.

Demographic information on patients evaluated via triple-TOF analysis

	Total	HRG	Stage					Age (yr)
	Total	HRG	0	I	II	III	IV	Mean±SD	Range
OVC^a)	30	-	-	11	2	12	4	53.7±10.6	37-78
Control	30	-	-	-	-	-	-	55.7±8.3	37-70
CRC	42	-	1	10	7	21	3	60.3±12.4	33-82
HBC	14	9	-	-	1	1	3	63.6±14.8	45-84
PC	21	4	-	-	4	2	11	65.0±9.6	48-82

Supplementary information on individual participants is given in S4-S8 Tables. S9 Table lists the sample collection sites.

TOF, time of flight; HRG, high risk group; SD, standard deviation; OVC, ovarian cancer; CRC, colorectal cancer; HBC, hepatobiliary cancer; PC, pancreatic cancer.

^a) Using 29 samples with available data.

Table 3.

The discriminatory capacity ratios of certain LMI pairs upon MALDI-TOF analysis

	Log₁₀(137.1690 m/z)	Log₁₀(496.5022 m/z)	Log₁₀(524.5614 m/z)
	Log₁₀(84.4119 m/z)	Log₁₀(709.7642 m/z)	Log₁₀(709.7642 m/z)
Sensitivity (%)	87.72	92.98	94.74
Specificity (%)	92.98	94.74	92.98
PPV (%)	92.59	94.64	93.10
NPV (%)	88.33	93.10	94.64
Accuracy (%)	90.35	93.86	93.86

LMI, low-mass-ion; MALDI-TOF, matrix assisted laser desorption ionization-time of flight; PPV, positive predictive value; NPV, negative predictive value.

Table 4.

The discriminatory capacities of OVC-related metabolites identified on triple-TOF analysis

Mass ion, mass value (m/z)/ retention time (min)	Total	Specificity		Volcano parameter		Fisher discriminant ratio
Mass ion, mass value (m/z)/ retention time (min)	Sensitivity (%)/Specificity (%)	Control (%)/HBC (%)	CRC (%)/PC (%)	p-value	Log₁₀ (fold-change)	Fisher discriminant ratio
137.0455/2.04	96.67/90.65	96.67/85.71	92.86/80.95	< 0.001	0.8476	1.439
138.0497/2.46	93.33/91.59	96.67/85.71	95.24/80.95		0.7730	0.8539
159.0270/2.46	93.33/91.59	100.0/85.71	97.62/71.43		0.6813	0.8990
137.0461/2.07	86.67/91.59	96.67/85.71	90.48/90.48		0.8013	1.530
137.0454/3.14	86.67/90.65	100.0/71.43	95.24/80.95		0.8039	1.341
359.1413/15.27	100.0/99.07	96.67/100.0	100.0/100.0		–1.257	1.704
381.1314/15.30	100.0/99.07	96.67/100.0	100.0/100.0		–1.846	1.443

OVC, ovarian cancer; TOF, time of flight; HBC, hepatobiliary cancer; CRC, colorectal cancer; PC, pancreatic cancer.

Table 5.

Seven candidate metabolites discriminating OVC

Mass ion^a), mass value (m/z)/ retention time (min)	Possible compound	Metabolite	H⁺ adduct, MW (Da)	Delta (ppm)^b)
137.0455/2.04	HMDB00157	Hypoxanthine	137.0458	2
138.0497/2.46		LMI isotopic pattern at 137.0455 m/z
159.0270/2.46	HMDB37759	2-Methylene-4-oxopentanedioic acid	159.0288	11
	HMDB60348	2-Maleylacetate	159.0288	11
	HMDB31210	Zymonic acid	159.0288	11
137.0461/2.07	HMDB00157	Hypoxanthine	137.0458	2
137.0454/3.14	HMDB00157	Hypoxanthine	137.0458	2
359.1413/15.27	HMDB01069	2-Phenylaminoadenosine	359.1462	14
381.1314/15.30	HMDB33883	3-O-Methylglycyrol	381.1333	5
	HMDB41236	2-(4-Hydroxyphenyl)-3,6-dimethoxy-8,8-dimethyl-4H, 8H-benzo[1,2-b:3,4-b']dipyran-4-one	381.1333	5
	HMDB14414	Chlorotrianisene	381.1252	16

OVC, ovarian cancer; MW, molecular weight.

^a) The mass-to-charge ratio (m/z) information used to search for candidate metabolites in the Human Metabolome Database (HMDB, http://www.hmdb.ca),

^b) Search condition: mass tolerance less than 20 ppm.

REFERENCES

1. Kim YH, Kim SC. Recent advances in the biomarkers for epithelial ovarian cancer. J Gynecol Oncol. 2011;22:219–21. Article PubMed PMC
2. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327–40. Article PubMed
3. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–56. Article PubMed PMC
4. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295–303. Article PubMed
5. Lee JH, Yoo BC, Kim YH, Ahn SA, Yeo SG, Cho JY, et al. Lowmass-ion discriminant equation (LOME) for ovarian cancer screening. BioData Min. 2016;9:32.Article PubMed PMC PDF
6. Lee JH, Kim KH, Park JW, Chang HJ, Kim BC, Kim SY, et al. Low-mass-ion discriminant equation: a new concept for colorectal cancer screening. Int J Cancer. 2014;134:1844–53. Article PubMed PMC
7. Kim K, Yeo SG, Yoo BC. Identification of hypoxanthine and phosphoenolpyruvic acid as serum markers of chemoradiotherapy response in locally advanced rectal cancer. Cancer Res Treat. 2015;47:78–89. Article PubMed PMC PDF
8. Yoo BC, Kong SY, Jang SG, Kim KH, Ahn SA, Park WS, et al. Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling. BMC Cancer. 2010;10:55.Article PubMed PMC PDF
9. Lorenzi M, Vannoni D, Leoncini R, Caldarone R, Marinello E. The determination of urinary oxypurines as markers of gastrointestinal tumors. Tumori. 1987;73:289–94. Article PubMed
10. Jung J, Jung Y, Bang EJ, Cho SI, Jang YJ, Kwak JM, et al. Noninvasive diagnosis and evaluation of curative surgery for gastric cancer by using NMR-based metabolomic profiling. Ann Surg Oncol. 2014;21 Suppl 4:S736–42. Article PubMed
11. Kyriakides M, Rama N, Sidhu J, Gabra H, Keun HC, El-Bahrawy M. Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy. Oncotarget. 2016;7:7216–26. Article PubMed PMC
12. Chan TC, Howell SB. Role of hypoxanthine and thymidine in determining methotrexate plus dipyridamole cytotoxicity. Eur J Cancer. 1990;26:907–11. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Preliminary Metabolomics Study Suggests Favorable Metabolic Changes in the Plasma of Breast Cancer Patients after Surgery and Adjuvant Treatment
Andrea Jiménez-Franco, Juan Manuel Jiménez-Aguilar, Marta Canela-Capdevila, Raquel García-Pablo, Helena Castañé, Cristian Martínez-Navidad, Pablo Araguas, Bárbara Malavé, Rocío Benavides-Villarreal, Johana C. Acosta, Alina Iuliana Onoiu, Navita Somaiah, J
Biomedicines.2024; 12(10): 2196. CrossRef
Circulating proteins as predictive and prognostic biomarkers in breast cancer
Hugo Veyssière, Yannick Bidet, Frederique Penault-Llorca, Nina Radosevic-Robin, Xavier Durando
Clinical Proteomics.2022;[Epub] CrossRef
Applications of MALDI-MS/MS-Based Proteomics in Biomedical Research
Laura Darie-Ion, Danielle Whitham, Madhuri Jayathirtha, Yashveen Rai, Anca-Narcisa Neagu, Costel C. Darie, Brînduşa Alina Petre
Molecules.2022; 27(19): 6196. CrossRef
Methylglyoxal Adducts Levels in Blood Measured on Dried Spot by Portable Near-Infrared Spectroscopy
Giuseppe Bonapace, Francesco Gentile, Nicola Coppedé, Maria Laura Coluccio, Virginia Garo, Marco Flavio Michele Vismara, Patrizio Candeloro, Giuseppe Donato, Natalia Malara
Nanomaterials.2021; 11(9): 2432. CrossRef
Identification of New Peptide Biomarkers for Bacterial Bloodstream Infection
Yating Ma, Xinyu Wen, Yi Kong, Chen Chen, Ming Yang, Shang He, Jianan Wang, Chengbin Wang
PROTEOMICS – Clinical Applications.2020;[Epub] CrossRef
Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis
Kexin Li, Yuqing Pei, Yue Wu, Yi Guo, Wei Cui
Journal of Ovarian Research.2020;[Epub] CrossRef
Comparative cerebrospinal fluid metabolites profiling in glioma patients to predict malignant transformation and leptomeningeal metastasis with a potential for preventive personalized medicine
Ji Hye Im, Byong Chul Yoo, Jun Hwa Lee, Kyung-Hee Kim, Tae Hoon Kim, Kyue-Yim Lee, Jong Heon Kim, Jong Bae Park, Ji-Woong Kwon, Sang Hoon Shin, Heon Yoo, Ho-Shin Gwak
EPMA Journal.2020; 11(3): 469. CrossRef
Exploring Serum Metabolic Markers for the Discrimination of Ccrcc From Renal Angiomyolipoma By Metabolomics
Mingfeng Xiang, Feng Du, Jing Dai, Ling Chen, Ruijin Geng, Huiming Huang, Baogang Xie
Biomarkers in Medicine.2020; 14(8): 675. CrossRef
Metabolomic Biomarkers in Gynecology: A Treasure Path or a False Path?
Igor Govorov , Stanislav Sitkin , Tatyana Pervunina , Alexey Moskvin , Denis Baranenko , Eduard Komlichenko
Current Medicinal Chemistry.2020; 27(22): 3611. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer

Cancer Res Treat. 2018;50(3):883-893. Published online September 18, 2017

DOI: https://doi.org/10.4143/crt.2017.275

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer

Fig. 1. Separation results obtained during one of the six repeats of matrix assisted laser desorption ionization-time of flight analysis. (A) Principal component analysis-based discriminant analysis (PCA-DA). (B) Preliminary low-mass-ion candidates. DS, discriminant score; OVC, ovarian cancer; BOT, benign ovarian tumor.

Fig. 2. Discriminatory results afforded by the ratios of low-mass ion pairs on matrix assisted laser desorption ionization-time of flight analysis. (A) Log10(137.1690 m/z)/Log10(84.4119 m/z). (B) Log10(496.5022 m/z)/Log10(709.7642 m/z). (C) Log10 (524.5614 m/z)/Log10(709.7642 m/z). OVC, ovarian cancer; BOT, benign ovarian tumor.

Fig. 3. Seven candidate metabolites suggested by triple-TOF analysis to be characteristic of ovarian cancer (OVC). (A) Figure shows relative amount of each candidate metabolites [Y-axis, Log10(mass peak area of low-mass ion)] in healthy women (control) and those with OVC, colorectal cancer (CRC), hepatobiliary cancer (HBC), and pancreatic cancer (PC). Low-mass ions (LMIs) of 137.0455 m/z, retention time (RT) 2.04 min; 138.0497 m/z, RT 2.46 min; 159.0270 m/z, RT 2.46 min; 137.0461 m/z, RT 2.07 min; 137.0454 m/z, RT 3.14 min; 359.1413 m/z, RT 15.27 min; 381.1314 m/z, RT 15.30 min. Of the seven LMIs, four with a 137.0455 m/z ion at RTs of 2.04-3.14 min were upregulated in sera from OVC patients; those LMIs were identified as hypoxanthine. (B) A volcano plot of low-mass ions detected on triple-TOF analysis.

Fig. 4. Identification of hypoxanthine upregulated in sera of ovarian cancer (OVC) patients. A low-mass ion of 137.0455 m/z (left panel, B) exhibited a retention time (RT) that differed slightly from that of hypoxanthine (left panel, A), but the tandem mass spectrometry (MS/MS) pattern (right panel, B) was exactly that of hypoxanthine (right panel, A).

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer

	Total	Stage				Age (yr)
	Total	I	II	III	IV	Mean±SD	Range
OVC	57	11	2	37	7	54.7±10.1	27-76
BOT	57	-	-	-	-	41.7±14.2	20-83

	Total	HRG	Stage					Age (yr)
	Total	HRG	0	I	II	III	IV	Mean±SD	Range
OVC^a)	30	-	-	11	2	12	4	53.7±10.6	37-78
Control	30	-	-	-	-	-	-	55.7±8.3	37-70
CRC	42	-	1	10	7	21	3	60.3±12.4	33-82
HBC	14	9	-	-	1	1	3	63.6±14.8	45-84
PC	21	4	-	-	4	2	11	65.0±9.6	48-82

	Log₁₀(137.1690 m/z)	Log₁₀(496.5022 m/z)	Log₁₀(524.5614 m/z)
	Log₁₀(84.4119 m/z)	Log₁₀(709.7642 m/z)	Log₁₀(709.7642 m/z)
Sensitivity (%)	87.72	92.98	94.74
Specificity (%)	92.98	94.74	92.98
PPV (%)	92.59	94.64	93.10
NPV (%)	88.33	93.10	94.64
Accuracy (%)	90.35	93.86	93.86

Mass ion, mass value (m/z)/ retention time (min)	Total	Specificity		Volcano parameter		Fisher discriminant ratio
Mass ion, mass value (m/z)/ retention time (min)	Sensitivity (%)/Specificity (%)	Control (%)/HBC (%)	CRC (%)/PC (%)	p-value	Log₁₀ (fold-change)	Fisher discriminant ratio
137.0455/2.04	96.67/90.65	96.67/85.71	92.86/80.95	< 0.001	0.8476	1.439
138.0497/2.46	93.33/91.59	96.67/85.71	95.24/80.95		0.7730	0.8539
159.0270/2.46	93.33/91.59	100.0/85.71	97.62/71.43		0.6813	0.8990
137.0461/2.07	86.67/91.59	96.67/85.71	90.48/90.48		0.8013	1.530
137.0454/3.14	86.67/90.65	100.0/71.43	95.24/80.95		0.8039	1.341
359.1413/15.27	100.0/99.07	96.67/100.0	100.0/100.0		–1.257	1.704
381.1314/15.30	100.0/99.07	96.67/100.0	100.0/100.0		–1.846	1.443

Mass ion^a), mass value (m/z)/ retention time (min)	Possible compound	Metabolite	H⁺ adduct, MW (Da)	Delta (ppm)^b)
137.0455/2.04	HMDB00157	Hypoxanthine	137.0458	2
138.0497/2.46		LMI isotopic pattern at 137.0455 m/z
159.0270/2.46	HMDB37759	2-Methylene-4-oxopentanedioic acid	159.0288	11
	HMDB60348	2-Maleylacetate	159.0288	11
	HMDB31210	Zymonic acid	159.0288	11
137.0461/2.07	HMDB00157	Hypoxanthine	137.0458	2
137.0454/3.14	HMDB00157	Hypoxanthine	137.0458	2
359.1413/15.27	HMDB01069	2-Phenylaminoadenosine	359.1462	14
381.1314/15.30	HMDB33883	3-O-Methylglycyrol	381.1333	5
	HMDB41236	2-(4-Hydroxyphenyl)-3,6-dimethoxy-8,8-dimethyl-4H, 8H-benzo[1,2-b:3,4-b']dipyran-4-one	381.1333	5
	HMDB14414	Chlorotrianisene	381.1252	16

Table 1. Demographic data on study participants evaluated via MALDI-TOF analysis

Supplementary information on individual participants is given in S1 and S2 Tables. S3 Table lists the sample collection sites.

MALDI-TOF, matrix assisted laser desorption ionization-time of flight; SD, standard deviation; OVC, ovarian cancer; BOT, benign ovarian tumor.

Table 2. Demographic information on patients evaluated via triple-TOF analysis

Supplementary information on individual participants is given in S4-S8 Tables. S9 Table lists the sample collection sites.

TOF, time of flight; HRG, high risk group; SD, standard deviation; OVC, ovarian cancer; CRC, colorectal cancer; HBC, hepatobiliary cancer; PC, pancreatic cancer.

Using 29 samples with available data.

Table 3. The discriminatory capacity ratios of certain LMI pairs upon MALDI-TOF analysis

LMI, low-mass-ion; MALDI-TOF, matrix assisted laser desorption ionization-time of flight; PPV, positive predictive value; NPV, negative predictive value.

Table 4. The discriminatory capacities of OVC-related metabolites identified on triple-TOF analysis

OVC, ovarian cancer; TOF, time of flight; HBC, hepatobiliary cancer; CRC, colorectal cancer; PC, pancreatic cancer.

Table 5. Seven candidate metabolites discriminating OVC

OVC, ovarian cancer; MW, molecular weight.

The mass-to-charge ratio (m/z) information used to search for candidate metabolites in the Human Metabolome Database (HMDB, http://www.hmdb.ca),